Objectives: The objective of this study was to determine the maternal PLAC1 protein levels in early and late onset preeclampsia.
INTRODUCTION
Preeclampsia (PE) is a multi-system disorder and a major cause of maternal and fetal mortality or serious morbidity. However, most affected pregnancies end up at term with good maternal and fetal outcomes [1, 2] . Gestational hypertensive disorders cause complications in approximately 5-10% of all pregnancies [3] . According to WHO2014 data, the second most common cause for maternal mortality is pregnancy-related hypertensive disorders (14%) after hemorrhage [4] . In most women, the clinical features first come into view after 34 weeks of gestation (late onset PE). However, 10% of women develop PE before the 34 th week of gestation (early onset PE) [5] . 2003 and 2008 studies of PE indicate that differences in its origins seem to result in phenotypic alterations of subtypes [5, 6] . Jackman SM, et al report that some proteins are involved in specific protein interactions with reference to a role at the maternal-fetal interface and are essential for normal placental development [7] . In Chang WL, et al there is evidence that suggests that Human placenta-specific protein-l (PLACI) is an important protein in placental development [8] . Jackman SM, et al also show that deficiency of placental PLAC1 protein results in hyperplastic placenta, and dysmorphic junctional zone [7] .
The aim of our study was to determine the maternal PLAC1 protein levels in early-and late-onset PE pregnancies as there is potential for the protein levels to play a role in placental dysfunction.
MATERIAL AND METHODS
The protocol of this study was approved by the Ethics Committee of the Planning and Coordination Center at Dr. Zekai Tahir Burak Women's Health Care, Education and Research Hospital (#18/2014) and informed consent was obtained from all participants before enrollment. The study followed the tenets of the Declaration of Helsinki [9] .
Between June and November 2014, 135 pregnant women who had been admitted to the perinatology department of a tertiary referral hospital were enrolled in the study. PE was defined as elevated blood pressure in a previously normotensive woman after 20 weeks of gestation, either ≥ 140/90 mmHg on two occasions at least four hours apart or ≥ 160/110 mmHg within a short interval (minutes apart); and a proteinuria of ≥ 300 mg in a 24-hour urine specimen [1] . In the absence of proteinuria, the diagnostic criteria consisted of new-onset hypertension together with thrombocytopenia, renal failure, poor liver function, pulmonary edema, or any visual symptoms [1] . Pregnancies with PE before 34 weeks of gestation were defined as early-onset preeclampsia, whereas pregnancies after 34 weeks were specified as late-onset PE. The control group was comprised of pregnant women with unremarkable pregnancy follow--ups. The exclusion criteria for the study and control groups were the presence of multiple pregnancies, systemic disease, a history of alcohol use or smoking and any chronic drug use.
On, admission, venous blood samples (10 cc) were collected in tubes containing ethylenediaminetetraacetic acid. The samples were centrifuged for 10 min and the plasmas were stored at -80°C for subsequent assay. The maternal serum PLAC1 protein levels were determined using a sandwich enzyme-based technique in accordance with the manufacturer's instructions. (Cusabio Biotech Co., Stratech Scientific Limited. United Kingdom). Results were expressed as ng/mL.
The Statistical Package for Social Sciences (SPSS) for Windows 23.0 (SPSS Inc., Chicago, IL) was used for the analysis of the data. The normality of the variables was assessed by the Shapiro-Wilk test. Differences between the two independent groups were compared by Student's t and Mann-Whitney U tests, where appropriate. The detection and false-positive rates of PLAC1 for the prediction of PE were estimated by using Receiver Operating Characteristic (ROC) curves analysis. A two-tailed p value of less than 0.05 was considered to be statistically significant. Calculations for sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and positive likelihood ratio were carried out. Also checked were the negative likelihood ratio and diagnostic odds ratio with their associated 95% CI.
RESULTS
Of the total of 135 pregnant women included in the study, 55 were at the < 34-week gestation and 80 were at ≥ 34-week gestation. Table 1 illustrates the clinical picture of the patients at ≥ 34 weeks of gestation. There were 30 patients with early onset PE and 25 in the control group. No significant differences were observed between the study group and control group in terms of their age, body mass index, gravida, gestational age, fetal biometric measurements, liver enzyme Table 2 illustrates the clinical picture of the pregnant women at the ≥ 34 th week of gestation. There were 45 patients with late onset PE and 35 in the control group. In patients with late onset PE, higher gravidity, higher systolic and diastolic blood pressure, elevated serum urea and creatinine values, 24-hour urine protein, lower femur length measurement and a low Apgar score at minute 5 were detected (p < 0.05). No statistically significant differences were found between the study and control groups with regard to their age, body mass index, gestational age, abdominal circumference and bi-parietal diameter measurements, neonatal birth-weight, liver enzymes and thrombocyte levels (p > 0.05).
Analysis of maternal serum PLAC1 levels did not reveal any significant differences between early onset PE and the control group (5.49 ± 12.24 g/mL vs. 4.96 ± 1.79 ng/mL, p = 0.422). However, the late onset PE patients exhibited significantly elevated levels of PIACI, in comparison with the healthy control group (8.25 ± 3.52 ng/ml vs. 6.83 ± 4.19 ng/mL, P = 0.026). The difference in PLAC1 levels between early onset PE and late onset PE was also significant (5.49 + 2.24 ng/mL vs. 8.25 ± 3.52 ng/mL, p = 0.001) (Tab. 3). No association was found between the severity of the disease and PLAC1 levels in either the early-onset PE or late-onset PE groups (Tab. 4).
The area under the ROC curve of the PLAC1 for earlyand late-onset PE was 0.563 and 0.646 with p values of 0.422 and 0.026 respectively. The area under the ROC curve of the PLAC1 in PE was 0.613 with p value = 0.024. The cut--off value for PLAC1 was 6.19 ng/mL with sensitivity of 56% (95% CI 44.1-67.3), specificity of 63%; (95% CI 49.9-75.1), and a diagnostic odds ratio of 2.2 (95% CI 1.1-4.4) (p value -0.037). The cut-off value for PLAC1 was 7.2 ng/mL with sensitivity: 43% (95% CI 31.5-54.6) and specificity: 78% (95% CI 65.5-87.5) and a diagnostic odds ratio: 2.69 (95% CI 1.25-5.79) (p value = 0.016) (Tab. 5). 
DISCUSSION
The present study showed an increase in maternal serum PLAC1 protein levels in late onset PE compared with the control and the early-onset PE groups. However, no association was established between the severity of PE and PLAC1 levels in either the early-or late-onset groups.
Though many theories have been proposed, the etiology of PE remains unknown. Impaired placentation, oxidative stress, thrombocyte and thrombin activation are among the pathogenetic mechanisms of PE together with endothelial dysfunction, imbalance of angiogenesis and intravascular inflammation [10] . Valensise et al. and von Dadelszen et al. reported that the variety in the pathophysiology of these disorders results in the different presentations of the disease (early-and late-onset PE) [5, 6] . Vatten et al. reported that placental dysfunction constitutes the basis of early-onset PE, whereas the composition of other factors may play a role in the development of the late-onset of the disorder [11] . Fant et al. found that apoptotic changes within placental villus trophoblast and leakage from the damaged placental villus trophoblast due to hypoxia or oxidative stress were the causes of the increase in plasma proteins in preeclamptic women [12] .
Cocchia et al. recently identified a placenta-specific gene on the Xq26 chromosome as the PLAC1 gene and it has been shown that the gene expression is observed from the beginning of pregnancy until the end in the human placenta [13, 14] . The PLAC1 gene may facilitate trophoblastic interactions peculiar to the placental-uterine interface [13] and may constitute a marker of placental development [15] . PLAC1 mRNA expression is restricted to cells of trophoblastic lineage [13, 14, 16] . Detectable expressions of PLAC1 mRNA are not observed in adult or fetal tissues. However, recent studies demonstrated decreased levels in testis and cerebellum [17] . PLAC1 is localized in human placental syncytiotrophoblast [16, 18] . These observations are indications of the PLAC1 polypeptide being a membrane-associated protein.
Whether PLAC1 is localized extracellularly, intracellularly, or is, in fact, an integral membrane component that becomes internalized is still not clear from these studies. Human amniotic fluid (16-18-week gestation) and maternal serum (25-33 weeks) analysis show no identification of the soluble PLAC1 protein in these compartments. This suggests that the PLAC1 polypeptide does not circulate. However, it acts locally at the level of the trophoblast [12] .
The restricted nature of PLAC1 expression suggests it might serve as a useful biomarker that is indicative of functional disruptions at the maternal-fetal interface. This explanation was supported by Concu et al. [15] in their study which demonstrated that PLAC1 mRNA can be found in maternal serum as early as the 8th week of gestation and during pregnancy. The half-life of circulating fetal DNA increases fourfold in patients with preeclampsia [19] . The occurrence of higher circulating concentrations of the PLAC1 protein, observed in preeclampsia, might be contributed by similar mechanisms. Kodama et al. demonstrated that cell-free mRNA levels of PLAC1 were eight times higher in preeclamptic patients compared with their control group [20] . In previous studies, PLAC1 gene expression was reported as higher in PE patients compared with results for control groups [21, 22] . Farina et al. showed that there is a decre- [23] . Subsequent studies reported high levels of circulating PLAC1 mRNA in preeclampsia. These were in direct relation to the severity of the disease [22] . Ng et al. suggested different ways to clarify the fluctuations in circulating PLAC1 mRNA with PE [24] . The first elevated apoptosis that occurs within the villous trophoblast during PE [25] may have a link to the increased release of trophoblast-specific mRNA's and the shedding of membrane particles into the maternal plasma [20] . PLAC1 mRNA concentrations are a function of PE severity and the time of onset. These concentrations are higher in early-onset PE than in late-onset PE [22, 26] . This is the first study in the literature evaluating maternal serum PLAC1 protein levels in early-and late--onset PE. We found that late-onset PE was associated with higher levels of maternal serum PLAC1 protein. Our findings also revealed that serum PLAC 1 levels were notably higher in pregnant women with late-onset PE when compared with those with early-onset. However, PLAC1 protein levels were not influenced from the severity of the disease in PE groups. The cellular function of PLAC1 remains unknown. However, it is believed to be associated with the membrane, and it was linked to trophoblast differentiation [7, 18] . It is also a possibility that the higher levels of PLAC1 are related to an abnormal interaction between trophoblast and uterine tissues which induces a defective vascular remodeling of maternal spiral arteries leading to a non-invasion of trophoblast and placental insufficiency [27, 28] . After all, our study has some limitations. As a potential effect of gestational age, the PLAC1 may manifest changes during pregnancy. More comprehensive studies are needed to reach a better conclusion and to provide percentile ranks for the pregnancy weeks.
In conclusion, the results established by our study showed that PLAC1 protein levels were significantly elevated in pregnant women with late-onset PE compared with the healthy control group. Future studies are necessary to establish whether PLAC 1 protein levels may be used as a screening tool for late-onset PE.
